Sentences with phrase «of an oncology treatment»

Merck is increasingly reliant on the blockbuster medicine, which is positioned to become the leading player in a new generation of oncology treatments and rival Bristol - Myers Squibb's Opdivo.

Not exact matches

These products — largely innovative and pricey specialty medications that include breakthrough Hepatitis C treatments and immuno - oncology drugs — reflect the increased productivity and improved pipelines of pharma's R&D departments in recent years.

Shares of cancer - focused biotech Clovis Oncology soared nearly 50 % in early Monday trading on the strength of clinical trial results for its ovarian cancer treatment Rubraca.

Johnson & Johnson's cancer treatment Zytiga significantly cut the death risk for newly - diagnosed, advanced prostate cancer patients by 38 %, according to data unveiled at the ongoing American Society of Clinical Oncology (ASCO) annual meeting this weekend.

For example, Watson for Oncology can summarize the key medical attributes of a cancer patient and rank the best treatment options based on the data it has access to.

It can be everything from an über - helpful call - center rep to an oncology adviser, recommending cancer treatments on the basis of a patient's genetic profile and thousands of clinical trials and medical journal articles it has analyzed.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Sierra Oncology, Inc., a clinical stage drug development company focused on advancing next - generation DNA damage response therapeutics for the treatment of patients with cancer, went public near $ 29 in July 2015, then began a downtrend that continued through a June 2017 all - time low of $ 1.10.

Predicine has launched a new liquid biopsy panel called PredicineATLAS, which covers 600 genes and offers a readout of patients tumor mutational burden to help inform and assess immuno - oncology treatment.

These NDs have training in oncology - the university they attended has an integrative cancer treatment facility as part of its training.

While justifying his call for allocation of oil block to cancer treatment, he said a Mevavoltage cancer therapy machine is available for 33 million Nigerians as against four to about 200,000 Australians, adding, «most patients have little or no access to Radiation Oncology services».

As a matter of urgency, we need to train more healthcare professional (doctors, nurses, and pharmacist) in paediatric oncology, expand treatment access to at least three others centres (Tamale, Cape Coast and Volta regions); and equip these facilities with good Labourites to be able to detect both solid and blood cancers.

Dr. Mohamad Younes of New York Oncology Hematology joins Medical Monday to discuss immunotherapy treatment of cancer.

«This is a win - win - win for patients, payers, and employers,» Bekelman said, «The field of radiation oncology should be recognized for technical advances in clinical care that have achieved safe, effective, curative treatment for prostate cancer in fewer weeks.»

That's how Charles Sawyers, a 2009 Lasker Award winner and chair of human oncology and pathogenesis at Memorial Sloan - Kettering Cancer Center in New York City, made the connection with Bristol Myers Squibb (BMS) that led to second - generation treatments for chronic myeloid leukemia (CML).

Two complementary papers published back - to - back recently in the journal Radiotherapy and Oncology and the Journal of Thoracic Oncology outline the treatment success at Wake Forest Baptist.

However, the majority of patients develop treatment - resistant tumors, and only 10 to 15 percent of these patients survive long term, says Ie - Ming Shih, M.D., Ph.D., the Richard W. TeLinde Distinguished Professor in the department of Gynecology and Obstetrics, who led the study with Tian - Li Wang, Ph.D., an associate professor of pathology and oncology at the Johns Hopkins University School of Medicine.

«This study's results can have practice changing implications on how future prostate cancer trials are designed in terms of identifying the men for these studies who are at high risk for early death due to ineffective initial treatment for their prostate cancer,» stated Anthony Victor D'Amico, MD, PhD, chief, Genitourinary Radiation Oncology, Brigham and Women's Hospital and senior author of the study.

«Patients diagnosed with early - stage prostate cancer — and that's the vast majority of patients with this disease — face many treatment options that are thought to be similarly efficacious,» said Ronald C. Chen, MD, MPH, UNC Lineberger member and associate professor in the UNC School of Medicine Department of Radiation Oncology.

For men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely - hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

«That's because we desperately need a new strategy to treat this lymphoma — many patients are resistant to currently available treatments,» says the study's senior investigator, Dr. Ari Melnick, Gebroe Family Professor of Hematology / Oncology and director of the Raymond and Beverly Sackler Center for Biomedical and Physical Sciences at Weill Cornell.

NRG Oncology / RTOG 0232 is a phase III, multi-institutional trial conducted at 68 cancer centers throughout the U.S. and Canada from 2003 to 2012 to assess whether adding EBT to transperineal interstitial permanent brachytherapy conveyed an additional benefit in progression free survival (PFS), or control of the cancer growth, at five years following treatment.

These preclinical findings, published online ahead of print in the International Journal of Oncology, provide evidence for a potential therapeutic approach that will restore sensitivity to chemotherapy and improve treatment of inflammatory breast cancer tumors.

«Our preclinical data suggest that combining low doses of these inhibitors will enhance the clinical effects of both drugs as a potential treatment for patients with AML,» says the senior author, Feyruz V. Rassool, PhD, associate professor of radiation oncology at the University of Maryland School of Medicine (UM SOM) and a researcher at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).

These include the ability to bring new, innovative products to the market; progress in oncology, such as the approval of Genentech's drug Avastin for breast cancer and advances in the use of gene therapy, despite some setbacks; continuing progress in research on stem cells; the emergence of treatments for previously untreated diseases; and solutions for food and fuel shortages, such as biocrops and biofuels.

«Our work could also contribute to ongoing efforts in immuno - oncology and the treatment of cancer,» explained Tao Xu, postdoctoral scholar in Ding's laboratory and first author of the study.

«For someone like myself, in this kind of work, this is the kind of result that you get to see once in your career,» said study co-senior author Philippe Armand, MD, PhD, medical oncologist in the Hematologic Oncology Treatment Center at Dana - Farber.

The results of the clinical trial, which appear in the Journal of Clinical Oncology, show that the treatment is safe and effective against five different viruses, including one for which there was no effective treatment before.

TRINOVA - 2 is evaluating pegylated liposomal doxorubicin in combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA - 3, also known as ENGOT - Ov2 and Gynecologic Oncology Group — 3001, is studying the use of trebananib in front - line treatment adding it to carboplatin / paclitaxel.

«Our findings could have a significant impact on the treatment of autoimmune diseases, as well as on stem cell and immuno - oncology therapies,» said Gladstone Senior Investigator Sheng Ding, PhD, who is also a professor of pharmaceutical chemistry at the University of California, San Francisco.

Phase I / II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK + non-small cell lung cancer (NSCLC), with 58 of 78 ALK + patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

«We found very high response rates to this treatment combination, which has the added benefit of having a much reduced risk of long - term organ damage compared to the highly toxic chemotherapy agents typically used for patients with relapsed Hodgkin lymphoma,» says Dr. Kelly, who is Program Director of the Pediatric Hematology / Oncology Service Line at the Women & Children's Hospital of Buffalo and holds an additional faculty appointment with the University at Buffalo.

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur.

This image shows F. Stephen Hodi, M.D., director of the Melanoma Treatment Center and director of the Center for Immuno - Oncology at Dana - Farber.

Presenting these results at the 3rd ESTRO Forum in Barcelona, Spain, today (Monday) Professor James Morris, from the Department of Radiation Oncology, Vancouver Cancer Centre, British Columbia Cancer Agency (BCCA), Vancouver, Canada, will say that the ASCENDE - RT1 trial is the first and only existing trial comparing low - dose - rate prostate brachytherapy (LDR - PB) for the curative treatment of prostate cancer with any other method of radiation therapy delivery.

Commenting on the results, Professor Johan Vansteenkiste, Professor of Medicine, Catholic University Leuven, and Chief Oncology Physician, Unit of Respiratory Oncology, University Hospital KU Leuven, Belgium, said: «This study may change current practice for the treatment of patients with advanced NSCLC.

All patients received standard first - line treatment of FOLFIRI plus cetuximab until disease progression or unacceptable toxicity, as previously reported (Ciardiello et al, Annals of Oncology 2014).

«We found that pemetrexed combined with cisplatin is less toxic, well tolerated, and should be developed for further treatment of cervical cancer,» said gynecologic oncology specialist Dr. David Miller, Professor of Obstetrics and Gynecology and a member of the Harold C. Simmons Cancer Center.

The lab is also working with the Breast Oncology Program at UCSF to make this data part of an adaptive clinical trial called I - SPY, which lets researchers identify the most effective therapies based on patient molecular profiling, and is collaborating with members of the UCSF Institute for Computational Health Sciences (ICHS) to put these and other public data into a centralized database that clinicians can access through an app to help make the most appropriate treatment decisions.

«Other studies have looked at racial disparities in treatment and still others have focused on racial differences in survival rates of cancer patients, but our research attempted to go further by demonstrating the impact of race - based inequalities in cancer treatment on survival rates of black colorectal cancer patients,» said James D. Murphy, MD, MS, assistant professor and chief of the Radiation Oncology Gastrointestinal Tumor Service at UC San Diego Moores Cancer Center.

However, what our trial has shown is that although this is still the case, the proportion of women who will actually have a recurrence without radiotherapy is very small (less than 5 percent), five years after treatment,» said Ian Kunkler, F.R.C.R., professor of clinical oncology at the Edinburgh Cancer Research Center in the University of Edinburgh.

«This study demonstrates the value of testing lung cancer tissue for an ALK rearrangement, and it underscores the potential of cancer genomics to target cancer treatments to each patient,» says the study's senior author, Pasi A. Jänne, MD, PhD, who is the director of the Lowe Center for Thoracic Oncology of Dana - Farber.

As we are seeing more women survive breast cancer, we need to focus on long term survivorship issues and ensuring that women have access to this important part of treatment,» says study first author Reshma Jagsi, M.D., D.Phil., associate professor of radiation oncology at the University of Michigan Comprehensive Cancer Center.

Results of EORTC trial 26101 presented at The 20th Annual Scientific Meeting and Education Day of the Society for Neuro - Oncology showed that bevacizumab treatment in patients with progressive glioblastoma, despite prolonged progression - free survival, does not confer a survival advantage.

The studies, published in the October 12 issue of JAMA Oncology, suggest that men who inherit this variant would benefit from a personalized treatment plan that targets specific hormonal pathways.

The research, which appears in the journal The Lancet Oncology, should aid efforts to reduce and better manage the late effects of cancer treatment.

Cardio - oncology is a relatively new field of research, emerging as scientists and doctors understand the connections between cancer treatment and the heart.

«Greater diversity of bacteria in the gut microbiome is associated with both a higher response rate to treatment and longer progression - free survival,» said study leader Jennifer Wargo, M.D., associate professor of Surgical Oncology at MD Anderson.

They say their findings, being presented June 2 at the 50th annual meeting of the American Society of Clinical Oncology (ASCO), offered several clinical insights that could lead to different treatment strategies and perhaps influence staging of advanced melanoma.

Tryfonidis et al. discuss perspectives and future directions for the management of locally advanced breast cancer in Nature Reviews Clinical Oncology, and they see a need for not only standardizing treatment for this disease, but also for developing new therapies that could substantially improve outcome.